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Abstract
Single nucleotide variants (SNVs) within and surrounding the complement receptor 1 (CR1) gene show some of the strong-
est genome-wide association signals with late-onset Alzheimer’s disease. Some studies have suggested that this association 
signal is due to a duplication allele (CR1-B) of a low copy repeat (LCR) within the CR1 gene, which increases the number 
of complement C3b/C4b-binding sites in the mature receptor. In this study, we develop a triplex paralogue ratio test assay 
for CR1 LCR copy number allowing large numbers of samples to be typed with a limited amount of DNA. We also develop 
a CR1-B allele-specific PCR based on the junction generated by an historical non-allelic homologous recombination event 
between CR1 LCRs. We use these methods to genotype CR1 and measure CR1-B allele frequency in both late-onset and 
early-onset cases and unaffected controls from the United Kingdom. Our data support an association of late-onset Alzhei-
mer’s disease with the CR1-B allele, and confirm that this allele occurs most frequently on the risk haplotype defined by 
SNV alleles. Furthermore, regression models incorporating CR1-B genotype provide a better fit to our data compared to 
incorporating the SNV-defined risk haplotype, supporting the CR1-B allele as the variant underlying the increased risk of 
late-onset Alzheimer’s disease.
Introduction
Alzheimer’s disease (AD) is a common neurodegenerative 
disease with an increasing disease burden in an aging popu-
lation (Ballard et al. 2011). Familial early-onset AD can be 
caused by autosomal dominant variants in, for example, the 
amyloid precursor protein gene APP, the presenilin 1 gene 
PSEN1, and the presenilin 2 gene PSEN1 (Campion et al. 
1999). Sporadic early onset AD (EOAD), with an age-of-
onset of 65 years or less, is defined as disease in the absence 
of these classical familial early-onset AD mutations. How-
ever, 99% of AD cases are late-onset AD (LOAD), which is 
a complex disease with multiple environmental and genetic 
contributions to its etiology. The most important genetic 
variant affecting LOAD risk is the APOE*4 allele, which is 
a haplotype formed by rs429358-C and rs7412-C, generat-
ing a protein called apolipoprotein E4 (APOE4) carrying 
arginine residues at position 130 and position 176 (Corder 
et al. 1993, 1998). This variant is associated with a 2–3-fold 
increase in LOAD risk for carriers, and a 15-fold increase 
in risk for individuals homozygous for this variant (Farrer 
et al. 1997). Genome-wide association studies (GWAS) on 
large cohorts have robustly identified 23 other variants with 
smaller effect sizes (Lambert et al. 2009, 2013). Many of 
the genetic associations are with variants that lie within or 
near genes involved in the immune response. This has high-
lighted the importance of the immune response to amyloid 
plaque formation in Alzheimer’s disease, possibly mediated 
by microglial cells (Efthymiou and Goate 2017; Naj and 
Schellenberg 2017; Villegas-Llerena et al. 2016).
One of the genes implicated in LOAD risk by GWAS 
is the complement C3b/C4b receptor 1 gene CR1. The 
receptor encoded by this gene is expressed on the surface 
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of leukocytes and erythrocytes, and binds the C3b frag-
ment of complement C3, and the C4b fragment of comple-
ment C4, as well as complement C1q. These interactions 
are important in the clearance of antibody-antigen immune 
complexes from the blood circulation, and in the phagocyto-
sis of complement-tagged pathogens. Complement receptor 
1 is also involved in the inflammatory response to injured 
tissue (Holers 2014).
Alleles at several SNVs both proximal, distal and within 
the CR1 gene have been identified as associated with LOAD, 
and these alleles are on a single risk haplotype that spans the 
CR1 gene (Corneveaux et al. 2010; Lambert et al. 2009; Luo 
et al. 2014). Identifying the variant within this haplotype 
that is functionally responsible for the genetic association 
is challenging, yet correct identification will allow a func-
tional genetic approach to determine the consequences of the 
variation in CR1 function and, therefore, how that variation 
contributes to LOAD risk. As previously observed, there 
are at least 60 missense variants within the risk haplotype 
(Corneveaux et al. 2010). and it has been suggested that a 
rare missense variant rs4844609 might be responsible for the 
observed association (Keenan et al. 2012) but this observa-
tion has not been supported (Van Cauwenberghe et al. 2013).
CR1 is known to contain an intragenic copy number vari-
ant (CNV) that alters the number of exons while maintaining 
the reading frame of the protein. The copy number variant is 
due to variable numbers of a tandemly arranged 18 kb repeat 
unit called a low copy repeat (LCR) (Crehan et al. 2012; Vik 
and Wong 1993; Wong et al. 1989; Wong et al. 1983). Each 
LCR contains eight exons, which together encode a C3b/
C4b binding domain such that high copy numbers of the 
LCR result in a longer CR1 molecule with more C3b/C4b 
binding domains (Fig. 1). The CR1 CNV has four alleles: 
CR1-A with two LCRs, CR1-B with three LCRs, CR1-C 
with one LCR and CR1-D with four LCRs. Each allele can 
be, therefore, represented by the copy number of the LCR 
domains. Alleles CR1-A, CR1-B and CR1-C are also known 
as CR1-F, CR1-S and CR1-F′, respectively, in the literature, 
based on their mobilities in protein electrophoresis. Previous 
studies have shown that CR1-A is the most frequent allele 
in individuals of European origin with a frequency of 0.87. 
CR1-B is the next most frequent, at a frequency of 0.11, 
with CR1-C and CR1-D at frequencies of 0.02 and < 0.01, 
respectively (Moulds et al. 1996).
Although the CR1 LCR CNV affects protein sequence 
quite dramatically, it is not directly assayed by current 
GWAS. Nevertheless, the association signal observed with 
SNV haplotypes might be due to a CR1 LCR CNV allele if 
that allele was on that particular SNV haplotype and, there-
fore, in linkage disequilibrium with the SNV alleles that 
show association with LOAD. A previous study tested the 
association of the CR1-B allele with LOAD on a cohort of 
Flemish Belgian patients (n = 1039) and controls (n = 844), 
and showed that CR1-B carriers showed an increased risk of 
LOAD (OR 1.32, 95% CI 1.03–1.69, p = 0.028). They repli-
cated their result on a sample of French patients (n = 1393) 
and controls (n = 610) (OR = 1.33, 1.02–1.74, p = 0.039), and 
showed that this represented the same association signal as 
that for the SNVs rs4844610 and rs1408077 (Brouwers et al. 
2012).
Fig. 1  Structure of the human CR1 and CR1L region showing the dif-
ferent CNV alleles. The CR1 and CR1L genes are shown, with SNVs 
that have been reported as associated with late-onset Alzheimer’s dis-
ease in GWAS shown in green. The duplicated structure of the region 
is shown, with pale/dark orange boxes showing repeated regions that 
are ~ 92% similar between CR1 and CR1L, and pale/dark blue boxes 
showing the LCR regions that are ~ 99% similar. The genome assem-
bly shows a CR1-B allele, comprised of LCR1, LCR2 and LCR1′ 
which is a fusion of LCR2 and LCR1. The structure of the alternative 
alleles (CR1-A, CR1-C and CR1-D) are shown below, with hatching 
indicating unclear origin of the LCR. The location of the amplifica-
tion products for the three PRT assays are indicated, with the test 
amplicons generated from the pale orange CR1 repeats, and the refer-
ence amplicons generated from the dark orange CR1L  repeat. Based 
in part on the UCSC Genome browser hg38 assembly
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Our study aimed first to develop a robust assay based on 
the paralogue ratio test and junction-fragment PCR for CR1 
LCR CNV, in particular for the intragenic duplication allele 
CR1-B, to facilitate further studies. Second, we aimed to use 
our methods to replicate the previous association of CR1 and 
LOAD in a larger cohort. We also investigate the association 
of CR1-B in a cohort of EOAD to test for a stronger risk 
effect as a result of a more pronounced phenotype.
Methods
Samples
Lymphoblastoid cell lines derived from the 1000 Genomes 
project samples (Coriell Cell Repositories, Camben, NJ) 
were grown using the standard conditions recommended 
by the supplier, and DNA isolated using a standard phe-
nol–chloroform-based approach. UK samples were pur-
chased as part of Human Random Controls plate 1 (HRC-1) 
from Public Health England.
Human DNA samples were obtained from the Alzhei-
mer’s Research Trust (ART) Collaboration [University of 
Nottingham; University of Manchester; University of South-
ampton; University of Bristol; Queen’s University, Belfast; 
the Oxford Project to Investigate Memory and Ageing 
(OPTIMA), Oxford University]; All case samples were diag-
nosed as either definite (post mortem confirmed) or probable 
Alzheimer’s disease (AD) according to National Institute 
of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Associa-
tion (NINCDS-ADRDA), and the Consortium to Establish 
a Registry for Alzheimer’s Disease (CERAD) guidelines. 
All samples used in this study were received with informed 
consent and were approved by the local Ethics Committee.
The 449 sporadic EOAD samples had an age of disease 
onset (AAO) ≤ 65 years of age, the 1436 LOAD samples 
had an AAO > 65 years of age and the 1359 controls had an 
age at death (AAD) > 65 years of age. Where AAO was not 
documented, it was derived assuming 8 years disease dura-
tion from age at death (Brookmeyer et al. 2002), or age at 
sampling (AAS) was used with the understanding it would 
approximate to disease onset (Tables 1, 3).
DNA was extracted from blood or brain tissue using a 
standard phenol chloroform extraction method. DNA qual-
ity and quantity was assessed via gel electrophoresis and 
NanoDrop™ 3300 spectrometer, respectively.
CR1 copy number estimation from sequence read 
depth data
Sequence alignment files in .bam format and correspond-
ing index files in .bai format were downloaded from the 
European Bioinformatics Institute (ftp.1000g enome s.ebi.
ac.uk/vol1/ftp/data_colle ction s/1000_genom es_proje ct/). 
Using samtools software (using the command samtools view 
-c -F 4 input.bam target_region), the number of mapped 
reads was counted across two intervals (GRCh37 chr1:207, 
697, 239–207, 751, 921 test region, GRCh37 chr1:207, 953, 
949–208, 008, 574 reference) for each of the samples ana-
lysed as part of the 1000 Genomes project (CEU individuals 
for Salt Lake City, Utah, Chinese individuals from Beijing, 
Japanese individuals for Tokyo and Yoruba individuals from 
Ibadan, Nigeria). A ratio of the reads from the copy num-
ber variable region:non-copy number variable region was 
taken as an estimate of CR1 intragenic copy number. Data 
are available in dbvar accession nstd159 at ncbi.nlm.nih.
gov/dbvar.
CR1 paralogue ratio test
To determine CR1 intragenic copy number on large num-
bers, we decided to design three specific assay using the 
paralogue ratio test (PRT), a form of competitive PCR that 
amplifies a test and reference locus using common prim-
ers, and uses the ratio of test and reference amplification 
products as a measure of copy number (Armour et al. 2007; 
Hollox 2017) (Supplementary Table 1). For each PCR, 
5–10 ng genomic DNA was amplified in a final volume of 
10 µl, containing 0.5 units Taq DNA polymerase (KAPA), 
0.5 µl of 10 µM forward primer, 0.5 µl of 10 µM reverse 
primer and 1 µl of 10xPCR mix (10xPCR mix = 50 mM 
TrisHCl pH8.8@25  °C, 12.5 mM ammonium sulphate, 
1.4 mM  MgCl2, 125 µg/ml BSA (Ambion), 7.5 mM 2-mer-
captoethanol and each dNTP (Promega) at a concentration of 
200 µM). Following PCR amplification in an Applied Bio-
systems Veriti thermal cycler at 95 °C for 2 min, followed 
by between 24 and 27 cycles of 95 °C for 20 s, 61–63 °C 
for 20 s and 72 °C for 20 s, and finally an elongation step at 
Table 1  Characteristics of EOAD cohort and controls
Cases Controls
Total N (individuals) 449 184
Age (median-range) years 57 (37–65) 74 (65–100)
Sex (males, females) 230,219 92,92
APOE*4 −/− 189 136
APOE*4 +/− 199 46
APOE*4 +/+ 61 2
CR1-B −/− 293 120
CR1-B +/− 139 57
CR1-B +/+ 17 7
Excluded with missing data 0 0
N used for association analysis 449 184
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72 °C for 10 min. Cycle number and annealing temperatures 
for each assay are given in supplementary Table 1.
Between 0.5 and 1 µl of the final product from each assay 
was combined and added to HiDi Formamide (Applied 
Biosystems) containing 1% MapMarker ROX-labelled size 
standard. Following denaturation of the mixture at 96 °C for 
3 min and snap cooling on ice, the products were run on an 
Applied Biosystems 3130xl capillary sequencer following 
the manufacturer’s instructions, and areas of the test and ref-
erence peaks recorded using Genemapper software. For each 
assay, seven samples of known CR1 LCR copy number were 
analysed with each experiment (Supplementary Table 2). 
These samples were chosen from the HapMap phase I panel, 
with copy number inferred from previous array CGH data 
(Conrad et al. 2009) or from preliminary experiments with 
multiple PRTs. PRT values were normalised using the values 
from the seven positive controls to generate an estimated 
copy number value.
Calling integer copy number from CR1 PRT data
Data from PRT1, PRT2 and PRT3 were concordant across 
the 1000 Genomes samples analysed so an average was 
taken to represent copy number, and normalised so that 
the standard deviation of the data was 1. For each cohort, 
a Gaussian mixture model of four or five components was 
fitted to the data using the CNVtools software implemented 
in the statistical language R v.3.2.3, with each component 
representing a integer copy number class (Barnes et al. 
2008). Samples were then assigned to each component with 
a posterior probability, and the component to which they 
were assigned reflected integer copy number call. A statistic 
Q, which is defined as the ratio of the separation of adjacent 
component means divided by the within-component stand-
ard deviation, averaged across all components of the mixture 
model, was calculated for each cohort. This represents the 
degree of clustering of the raw normalised data about integer 
copy number values (Barnes et al. 2008). PRT data from the 
1000 Genomes samples analysed is available at dbvar acces-
sion nstd159 at ncbi.nlm.nih.gov/dbvar.
CR1 junction fragment analysis
PCR products were amplified from 5 to 10 ng genomic DNA 
in a final volume of 10ul, with 0.5 µl of 2.5 mM of each of 
dATP, dCTP, dGTP and dTTP, 0.5 units Taq DNA polymer-
ase (KAPA Biosciences) and 0.5 µl of a 10 µM solution of 
each PCR primer. The PCR primers were 5′-AAT GTG TTT 
TGA TTT CCC AAG ATC AG-3′ and 5′-CTC AAC CTC CCA 
AAG GTG CTA-3′, with a terminal 3′ locked nucleic acid 
base (underlined) to increase paralogue-specificity (Latorra 
et al. 2003). A touch-down PCR protocol was used, with an 
initial denaturation step of 95 °C for 2 min, followed by 20 
cycles of 95 °C for 30 s, 70 °C for 30 s decreasing by 0.5 °C 
every cycle to 60 °C, and 70 °C for 30 s. These 20 cycles 
were then followed by 15 cycles of 95 °C for 30 s, 60 °C for 
30 s and 70 °C for 30 s, then a final extension step of 70 °C 
for 5 min. Products were analysed using standard ethidium 
bromide stained agarose gels and visualisation under ultra-
violet light. Specificity of the PCR for CR1-B alleles was 
confirmed on a panel of 40 UK samples from the HRC-1 
collection previously typed using PRT.
SNP genotyping and linkage disequilibrium analysis
Genotyping for the CR1 GWAS index SNP (Lambert et al. 
2013), rs6656401, and rs3818361 was carried out using KASP 
assays using standard protocols (LGC, Middlesex). Pairwise 
linkage disequilibrium was calculated using a cubic exact equa-
tion approach implemented in CubeX (Gaunt et al. 2007).
Statistical analysis and sequence alignment
Clustal Omega was used for sequence alignment provided 
by the European bioinformatics Institute web server (www.
ebi.ac.uk), using default DNA options (Li et al. 2015; Siev-
ers et al. 2011). Case–control analysis was performed using 
logistic regression implemented in the statistical package 
RStudio v.1.0 implementing R v3.2.3.
Results
Development and validation of PRT assays for CR1 
copy number
Our first aim was to develop a simple robust approach to 
determine the diploid copy number of the LCRs within the 
CR1 gene, which could use small amounts of DNA from 
large clinical cohorts. The 92% similarity between the LCRs 
within CR1 and part of the CR1L gene allowed the design of 
three PRT assays to independently measure the copy number 
of LCR (Fig. 2a).
Analysis of 275 samples from the 1000 Genomes col-
lection showed high pairwise concordance (~ 80%) pair-
wise between the three individual PRT results, allowing 
an average to be taken of the three PRT results for each 
sample as representative of the copy number of the LCR. 
For each sample, the copy number estimate from the PRT 
was compared against the copy number estimated from Illu-
mina sequencing read depth data. The data showed a high 
degree of concordance, with data for both estimates cluster-
ing around integer copy number estimates. In particular, the 
PRT data shows clear distinct clusters, suggesting that it will 
call copy number accurately (Fig. 2b).
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Because our study was focused on the CR1-B duplication, 
distinguishing the CR1-A/CR1-B heterozygotes (diploid 
LCR copy number 5) from the CR1-A/CR1-A homozygotes 
(diploid LCR copy number 4) was particularly critical. To 
improve the reliability of distinguishing these genotypes, we 
developed a junction fragment PCR to specifically amplify 
the LCR1′ repeat. If the LCR1′ repeat was generated in 
the past by an equal crossover between the 98% identical 
LCR1 and LCR2 sequences, we would expect a switch 
from LCR1-like sequence to LCR2-like sequence within 
the LCR1′ sequence (Fig. 3). Using a multiple alignment 
strategy on LCR1, LCR1′ and LCR2 sequences from the 
human reference genome GRCh37, we identified the switch 
point and confirmed that this is the same switch point found 
in early characterisations of the CR1-B allele (Vik and Wong 
1993). Designing PCR primers flanking the switch point, 
with a forward PCR primer specific to the LCR2 sequence 
and a reverse PCR primer specific to the LCR1 will generate 
an amplification product from CR1-B alleles but not from 
CR1-A alleles (Fig. 3).
Association analysis of the CR1‑B allele 
with Alzheimer’s disease
We typed 449 EOAD cases and 184 controls for copy num-
ber using our PRT approach (Table 1), resulting in a dataset 
that showed clear clustering around integer copy numbers 
and good separation of clusters (Fig. 4a). The Q value, a 
measure of clustering quality of the resulting data, was 5.56, 
above the minimum threshold of 4 previously suggested to 
be adequate for case–control studies (Barnes et al. 2008). 
By calling the individuals with LCR diploid copy numbers 
of 5 and 6 (CR1-B heterozygotes and CR1-B homozygotes, 
respectively), we could infer CR1-B allele dose for each 
individual. We then used logistic regression with sex and 
ApoE*4 genotype as covariates to test for the association 
of CR1-B allele with EOAD, assuming an additive effect of 
the allele. We found no evidence of association (p = 0.936, 
Table 2). 
We then typed 1436 LOAD cases and 1175 controls for 
copy number using our PRT approach (Table 3). The Q value 
Fig. 2  Design and validation of paralogue ratio test to detect CR1 
LCR copy number. a Measuring copy number using the paralogue 
ratio test. A primer pair is designed so that it amplifies from the LCR 
regions (test) and also from a 92% similar region in CR1L (reference). 
Three independent tests are normalised against seven controls of 
known copy number, and average to obtain an estimate of copy num-
ber. b Comparison of CR1 PRT copy number estimate (x axis and his-
togram) against estimates from Illumina sequence read depth (y axis 
and histogram). Each point represents a different individual, points 
are distinguished by shape and colour indicating the final integer copy 
number call: red cross—3, green x-cross—4, blue diamond—5, cyan 
triangle—6
Fig. 3  Junction fragment PCR for CR1-B allele. A representation of 
the frequent CR1-B and CR1-A alleles. Paralogue-specific primers 
(light-blue and dark-blue) are used to amplify specifically a break-
point in LCR1′. Hatched repeats indicates uncertain recombinant ori-
gin
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for this cohort was lower (Q = 4.05), and this is reflected in 
the clustering of values (Fig. 4b), where there is significant 
overlap between copy number clusters. To improve calling 
of copy numbers 4 and 5 (i.e. CR1-B heterozygotes and 
homozygotes) the junction fragment PCR assay was also 
used on the LOAD cohort. We used logistic regression with 
sex, age and APOE*4 genotype as covariates to test for the 
association of CR1-B allele with LOAD, assuming an addi-
tive effect of the allele (Table 4). We confirmed the effect 
of APOE*4 allele on increasing LOAD risk (p < 2 × 10−16, 
odds ratio 3.25, 95% confidence intervals for odds ratio 2.78, 
3.82), and evidence of association of the CR1-B allele with 
an increased risk of LOAD (p = 0.0151, odds ratio 1.21, 95% 
confidence intervals for odds ratio 1.04, 1.42).
Relationship of CR1‑B with flanking SNV alleles
We next attempted to address whether the association we see 
explains the association at SNVs flanking the CR1 gene seen 
in genome-wide association studies. The strength of effect that 
we observe for the CR1-B allele (odds ratio 1.21, 1.04–1.42 
95% CI) is consistent with the effect seen for rs6701713-A 
Fig. 4  Distributions of PRT copy number data. Histograms showing 
the distribution of copy number values generated by PRT in a early 
onset cases and controls and b late onset cases and controls. X axis 
represents normalised PRT ratio, with Gaussian curves superimposed 
to indicate the calling of CR1 LCR integer copy number, from left to 
right: black—3 copies, green 4 copies, cyan, 5 copies, yellow 6 cop-
ies and black (right hand side) > 6 copies
Table 2  Association of CR1-B 
allele with EOAD Parameter B (95% CI) Odds ratio (95% CI) p value
Intercept 0.293 (− 0.0162, 0.606) 1.34 (0.984, 1.832) 0.0642
Sex (0 = male, 1 = female) 0.0200 (− 0.341, 0.382) 1.02 (0.711, 1.47) 0.914
APOE*4 allele 1.24 (0.919, 1.59) 3.48 (2.51, 4.93) 4.37 × 10−13
CR1-B allele 0.0133 (− 0.307, 0.341) 1.01 (0.735, 1.41) 0.936
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allele [odds ratio 1.16, 1.11–1.22 95% CI, (Naj et al. 2011)] 
and rs3818361-T allele [odds ratio 1.18, 1.13–1.24 95% CI, 
(Hollingworth et al. 2011)]. We analysed the pairwise linkage 
disequilibrium between these two SNVs in a subset of the 
LOAD cohort (526 cases, 101 controls). We found complete 
linkage disequilibrium (D′ = 1, r2 = 1) between rs6701713 
and rs3818361, indicating an A–T risk haplotype and a G–C 
non-risk haplotype, similar to previous findings (Mahmoudi 
et al. 2015). Linkage disequilibrium between both SNVs and 
CR1-B showed LD (D′ = 0.806, r2 = 0.576) with the CR1-B 
allele. The CR1-B allele occurred on the A–T risk haplotype 
(CR1B-rs6701713A- rs3818361T haplotype frequency 0.16) 
with CR1-B on the non-risk haplotype (CR1B-rs6701713G- 
rs3818361C) infrequent at a frequency of 0.03. This pattern of 
LD is consistent with the CR1-B allele explaining the associa-
tion observed at the flanking SNP alleles.
If the association of LOAD with the CR1-B allele 
explains the association at flanking SNP alleles then we 
would expect a stronger association of disease with the 
CR1 duplication compared to the SNP alleles. We analysed 
a subset of our cohort that had genotypes for rs6701713 
and rs3818361 as well as CR1-B genotype, using the same 
model used to analyse the full LOAD cohort. Due to limited 
DNA availability, this subset was small (478 cases and 96 
controls) and underpowered to detect evidence for an asso-
ciation a priori. Nevertheless, the association with CR1-B 
was stronger (p = 0.067, OR 1.52, 95% CI 0.99–2.44) than 
with either rs6701713A or rs3818361T (p = 0.56, OR = 1.13 
95% CI 0.76–1.72), and incorporating CR1-B rather than 
rs6701713A or rs3818361T into the logistic regression 
model provides a better fit to the data (Akaike’s information 
criterion = 469.99 vs 473.26).
Discussion
In this study, we develop a new approach to measuring the 
copy number variation (CNV) of LCRs within the CR1 gene 
using the paralogue ratio test (PRT), together with a junction 
fragment PCR specific for the CR1-B allele that carries three 
copies of the LCR. Accurate typing of multiallelic CNV at 
a large scale can be challenging (Cantsilieris et al. 2014) 
and two other approaches have been developed to measure 
this particular CNV. One approach uses multiplex amplicon 
quantification (Brouwers et al. 2012), and the other uses a 
PRT approach with a reference amplicon within LCR2 of the 
CR1 gene and a test amplicon within LCR1 of the CR1 gene, 
distinguished by sequence variants, and quantifying the 
amounts of test amplicon using DNA duplex melting pro-
files (Kisserli et al. 2017). A large scale comparison between 
these approaches has not yet been made, but by making our 
PRT data publically available on some 1000 Genomes DNA 
samples, which are themselves publically available, we hope 
to facilitate a comparison between these methods.
Using our PRT and junction fragment PCR approaches, 
we typed a case–control cohort of early-onset Alzheimer’s 
disease and a case–control cohort of late-onset Alzheimer’s 
disease for copy number of the LCR within the CR1 gene, 
inferring the CR1-B genotype. An association study of the 
CR1-B allele with EOAD showed no evidence of asso-
ciation, but an association study of the CR1-B allele with 
LOAD provided evidence of association of the CR1-B allele 
with increased LOAD risk, in agreement with previous stud-
ies. We also show that the CR1-B allele is on the LOAD 
risk haplotype identified by SNV-based GWAS, and that the 
CR1-B allele shows stronger evidence of association with 
LOAD than the risk SNV alleles identified by GWAS.
One limitation of the PRT approach, a limitation also 
shared by the two other methods mentioned above, is that 
it reports diploid copy number—i.e., the copy number 
summed over both alleles, rather than the true genotype. So, 
Table 3  Characteristics of LOAD cohort and controls
* Not all individuals had sex data
Cases Controls
N (individuals) 1436 1175
Age (median-range) years 75.1 (43–98) 73.2 (30–100)
Sex (males, females)* 569, 851 532, 639
APOE*4 −/− 605 863
APOE*4 +/− 670 286
APOE*4 +/+ 161 26
CR1-B −/− 935 839
CR1-B +/− 422 284
CR1-B +/+ 79 52
Excluded with missing age/sex data 256 170
N used for association analysis 1180 1005
Table 4  Association of CR1-B 
allele with LOAD number of 
cases and controls
Parameter B (95% CI) Odds ratio (95% CI) p value
Intercept − 2.36 (− 3.06, − 1.67) 0.0944 (0.0467, 0.189) 3.48 × 10−11
Sex (0 = male, 1 = female) 0.149 (− 0.0330, 0.330) 1.16 (0.967, 1.39) 0.109
Age onset/sampling 0.0242 (0.0153, 0.0334) 1.02 (1.02, 1.03) 1.48 × 10−7
APOE*4 allele 1.18 (1.02, 1.34) 3.25 (2.78, 3.82) < 2 × 10−16
CR1-B allele 0.193 (0.0378, 0.349) 1.21 (1.04, 1.42) 0.0151
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for example, a copy number of 5 could be a 3 allele and a 2 
allele, or a 4-1 or a 5-0. We assumed that all 5 copy individu-
als were 3-2, that is CR1-B/CR1-A and all 6 copy individuals 
were 3-3 CR1-B/CR1-B not 4-2 CR1-A/CR1-D. This could 
be an incorrect assumption leading to an overestimation of 
the frequency of the CR1-B allele. Previous work has shown, 
by western blotting of the CR1 protein, that in three out of 
eight individuals the true genotype was CR1-A/CR1-D not 
CR1-B/CR1-B, suggesting that a significant proportion of 6 
copy individuals may not be homozygous for CR1-B as we 
assume (Brouwers et al. 2012). To assess the validity of our 
assumption in our population, we estimated the population 
allele frequencies from the diploid copy number data of the 
EOAD cohort using the R script CNVice, which simultane-
ously tests for any departure of the inferred genotype fre-
quencies from Hardy–Weinberg equilibrium (Zuccherato 
et al. 2017). The relative probability of a genotype given 
the individual’s copy number was also calculated from these 
results. We found that 4-copy individuals had a 99.2% prob-
ability of being CR1-A homozygotes, 5-copy individuals had 
a 100% probability of being CR1-A/CR1-B heterozygotes 
and 6-copy individuals had a 100% probability of being 
CR1-B homozygotes, supporting our assumptions used in 
this study.
Although complement appears to have an important role 
in brain development and pathology, the mechanistic basis 
for the association of the CR1-B allele with LOAD remains 
unclear (Morgan 2018). From RNA-seq analysis, the CR1 
gene is mainly expressed in peripheral blood leucocytes and 
the spleen (Lappalainen et al. 2013) but the CR1 protein is 
also detected in the brain, probably restricted to astrocytes 
(Fonseca et al. 2016; Gasque et al. 1996). It has been sug-
gested that, because of its extra C3b-binding site, the CR1-B 
protein is more effective at inhibiting C3b complement frag-
ments, leading to a reduction in C3b-mediated opsonisation 
of Ab1-42 fragments (Brouwers et al. 2012). However, in the 
brain the CR1-B isoform is expressed at lower levels than 
CR1-A and is probably associated with increased comple-
ment activation; indeed, complement system is activated by 
Ab (Hazrati et al. 2012; Mahmoudi et al. 2015; Rogers et al. 
1992). Future studies need to focus on the functional effect 
of CR1-B allele in vivo, in combination with structural stud-
ies to determine the difference in protein structure encoded 
by the different CR1 alleles.
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